NCT05677971: An ongoing trial by Takeda
This trial is ongoing. It must report results 2 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05677971 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 6, 2023 |
| Completion date | Feb. 17, 2028 |
| Required reporting date | Feb. 16, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |